JP2007503202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007503202A5 JP2007503202A5 JP2006521193A JP2006521193A JP2007503202A5 JP 2007503202 A5 JP2007503202 A5 JP 2007503202A5 JP 2006521193 A JP2006521193 A JP 2006521193A JP 2006521193 A JP2006521193 A JP 2006521193A JP 2007503202 A5 JP2007503202 A5 JP 2007503202A5
- Authority
- JP
- Japan
- Prior art keywords
- cytotoxic
- maytansine
- formula
- conjugate according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48844703P | 2003-07-21 | 2003-07-21 | |
| PCT/US2004/023340 WO2005009369A2 (en) | 2003-07-21 | 2004-07-21 | A ca6 antigen-specific cytotoxic conjugate and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010262151A Division JP5643619B2 (ja) | 2003-07-21 | 2010-11-25 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503202A JP2007503202A (ja) | 2007-02-22 |
| JP2007503202A5 true JP2007503202A5 (cg-RX-API-DMAC7.html) | 2009-03-12 |
Family
ID=34102763
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521193A Pending JP2007503202A (ja) | 2003-07-21 | 2004-07-21 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2010262151A Expired - Fee Related JP5643619B2 (ja) | 2003-07-21 | 2010-11-25 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2014133794A Expired - Fee Related JP5997727B2 (ja) | 2003-07-21 | 2014-06-30 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2015237469A Expired - Fee Related JP6144749B2 (ja) | 2003-07-21 | 2015-12-04 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2017033672A Pending JP2017123857A (ja) | 2003-07-21 | 2017-02-24 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010262151A Expired - Fee Related JP5643619B2 (ja) | 2003-07-21 | 2010-11-25 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2014133794A Expired - Fee Related JP5997727B2 (ja) | 2003-07-21 | 2014-06-30 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2015237469A Expired - Fee Related JP6144749B2 (ja) | 2003-07-21 | 2015-12-04 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
| JP2017033672A Pending JP2017123857A (ja) | 2003-07-21 | 2017-02-24 | Ｃａ６抗原特異的な細胞毒性コンジュゲートおよびその使用方法 |
Country Status (26)
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6596503B1 (en) | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US9539348B2 (en) | 2000-08-18 | 2017-01-10 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CR20170291A (es) * | 2003-05-20 | 2017-07-27 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinóides |
| US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
| US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| MX2008002607A (es) * | 2005-08-22 | 2008-03-19 | Immunogen Inc | Un conjugado citotoxico ca6 antigeno-especifico y metodos para utilizar el mismo. |
| CN104804094A (zh) * | 2005-08-22 | 2015-07-29 | 伊缪诺金公司 | Ca6抗原特异性细胞毒性偶联物及其应用方法 |
| PL2019104T3 (pl) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne |
| PL2240516T3 (pl) * | 2007-12-26 | 2015-12-31 | Biotest Ag | Sposoby i środki do ulepszania nakierowania na komórki nowotworowe z ekspresją CD138 |
| PL2242772T3 (pl) * | 2007-12-26 | 2015-05-29 | Biotest Ag | Immunokonjugaty nakierowane na CD138 i ich zastosowanie |
| JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
| US9221914B2 (en) * | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
| RU2503687C2 (ru) | 2008-04-30 | 2014-01-10 | Иммьюноджен, Инк. | Сшивающие реагенты и их применение |
| JP2012526079A (ja) * | 2009-05-06 | 2012-10-25 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体の使用 |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
| TW201129384A (en) | 2010-02-10 | 2011-09-01 | Immunogen Inc | CD20 antibodies and uses thereof |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| EP2663647A4 (en) * | 2011-01-14 | 2015-08-19 | Redwood Bioscience Inc | POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD |
| CN103826661B (zh) | 2011-04-21 | 2019-03-05 | 西雅图基因公司 | 新的结合剂-药物缀合物(adc)及其用途 |
| EP2758430A4 (en) * | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
| WO2013083817A1 (en) | 2011-12-08 | 2013-06-13 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| JP2012161321A (ja) * | 2012-03-30 | 2012-08-30 | Immunogen Inc | Ｃａ６抗原特異的細胞傷害性コンジュゲート、および該コンジュゲートを用いる方法 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| US9844607B2 (en) | 2013-02-05 | 2017-12-19 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| SG10201707391QA (en) | 2013-02-05 | 2017-10-30 | Sanofi Sa | Immuno imaging agent for use with antibody-drug conjugate therapy |
| CN105051521B (zh) | 2013-03-15 | 2020-03-24 | 贝克曼考尔特公司 | 用于设计流式细胞术中的面板的系统和方法 |
| EP3027218A1 (en) * | 2013-08-02 | 2016-06-08 | Sanofi | Use of anti-muc1 maytansinoid immunoconjugate antibody for the treatment of solid tumors |
| JP6721507B2 (ja) | 2013-12-23 | 2020-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ｋｓｐ阻害剤との抗体薬物複合体（ａｄｃ） |
| WO2015138615A2 (en) * | 2014-03-12 | 2015-09-17 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| CN109147874A (zh) | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| KR20240023671A (ko) | 2014-09-03 | 2024-02-22 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
| TW201613930A (en) | 2014-09-03 | 2016-04-16 | Immunogen Inc | Cytotoxic benzodiazepine derivatives |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
| MX2018011627A (es) | 2016-03-24 | 2019-01-10 | Bayer Pharma AG | Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles. |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| KR102583006B1 (ko) | 2016-12-21 | 2023-09-27 | 바이엘 파마 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc) |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| CN116785450A (zh) | 2017-02-28 | 2023-09-22 | 伊缪诺金公司 | 具有自分解肽接头的类美登素衍生物和其缀合物 |
| WO2018195243A1 (en) | 2017-04-20 | 2018-10-25 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and conjugates thereof |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| EP3732178A1 (en) | 2017-12-28 | 2020-11-04 | ImmunoGen, Inc. | Benzodiazepine derivatives |
| CN113795264A (zh) | 2019-03-19 | 2021-12-14 | 瓦尔希伯伦私人肿瘤研究基金会 | 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法 |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| WO2022182415A1 (en) | 2021-02-24 | 2022-09-01 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2023150677A2 (en) * | 2022-02-03 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd38 binding molecules and uses thereof |
| EP4608429A1 (en) | 2022-10-25 | 2025-09-03 | Peptomyc, S.L. | Combination therapy for the treatment of cancer |
| EP4473974A1 (en) | 2023-06-07 | 2024-12-11 | Peptomyc, S.L. | Omomyc and kras inhibitors combination therapy for the treatment of cancer |
| TW202502371A (zh) | 2023-06-07 | 2025-01-16 | 瓦爾希伯倫私人腫瘤研究基金會 | 用於治療癌症的與ｂｒａｆ抑制劑的組合療法 |
| WO2024251846A1 (en) | 2023-06-07 | 2024-12-12 | Fundació Privada Institut D'investigació Oncològica De Vall Hebron | Combination therapy with mek inhibitors for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| CA2026147C (en) * | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ATE181571T1 (de) * | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DE69329503T2 (de) * | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US20030143233A1 (en) * | 1999-06-07 | 2003-07-31 | Neorx Corporation | Streptavidin expressed gene fusions and methods of use thereof |
| AU765588C (en) * | 1999-11-24 | 2004-12-16 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| US6596503B1 (en) * | 2000-08-18 | 2003-07-22 | East Carolina University | Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof |
| US6333410B1 (en) * | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| EP1258255A1 (en) * | 2001-05-18 | 2002-11-20 | Boehringer Ingelheim International GmbH | Conjugates of an antibody to CD44 and a maytansinoid |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| MXPA04003057A (es) * | 2001-10-04 | 2005-06-20 | Immunex Corp | Proteina 4 de enlace ul16. |
| EP1482972A4 (en) * | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES |
| US6716821B2 (en) * | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| NZ533933A (en) * | 2002-01-02 | 2008-06-30 | Genentech Inc | Compositions and methods for the diagnosis and treatment of glioma tumor |
| KR101424624B1 (ko) | 2003-05-14 | 2014-07-31 | 이뮤노젠 아이엔씨 | 약물 콘쥬게이트 조성물 |
-
2004
- 2004-07-21 CN CN201310444419.1A patent/CN103554261B/zh not_active Expired - Lifetime
- 2004-07-21 ES ES04778714T patent/ES2360403T3/es not_active Expired - Lifetime
- 2004-07-21 PT PT04778714T patent/PT1660513E/pt unknown
- 2004-07-21 CN CN2004800243313A patent/CN1922199B/zh not_active Expired - Lifetime
- 2004-07-21 NZ NZ598504A patent/NZ598504A/xx not_active IP Right Cessation
- 2004-07-21 JP JP2006521193A patent/JP2007503202A/ja active Pending
- 2004-07-21 EA EA200600275A patent/EA014640B1/ru not_active IP Right Cessation
- 2004-07-21 MX MXPA06000830A patent/MXPA06000830A/es active IP Right Grant
- 2004-07-21 CN CN201310020230.XA patent/CN103145844B/zh not_active Expired - Lifetime
- 2004-07-21 NZ NZ612796A patent/NZ612796A/en not_active IP Right Cessation
- 2004-07-21 CA CA2532430A patent/CA2532430C/en not_active Expired - Fee Related
- 2004-07-21 WO PCT/US2004/023340 patent/WO2005009369A2/en not_active Ceased
- 2004-07-21 EP EP04778714A patent/EP1660513B9/en not_active Expired - Lifetime
- 2004-07-21 AU AU2004258955A patent/AU2004258955C1/en not_active Ceased
- 2004-07-21 BR BRPI0412879A patent/BRPI0412879A8/pt not_active Application Discontinuation
- 2004-07-21 US US10/895,135 patent/US20050123549A1/en not_active Abandoned
- 2004-07-21 AT AT04778714T patent/ATE496944T1/de active
- 2004-07-21 KR KR1020127013238A patent/KR20120059657A/ko not_active Ceased
- 2004-07-21 SI SI200431646T patent/SI1660513T1/sl unknown
- 2004-07-21 KR KR1020157031117A patent/KR101672664B1/ko not_active Expired - Fee Related
- 2004-07-21 KR KR1020067001429A patent/KR101263950B1/ko not_active Expired - Fee Related
- 2004-07-21 HR HR20110302T patent/HRP20110302T1/hr unknown
- 2004-07-21 KR KR1020127024607A patent/KR20120113811A/ko not_active Ceased
- 2004-07-21 KR KR1020147008527A patent/KR101565721B1/ko not_active Expired - Fee Related
- 2004-07-21 DE DE602004031239T patent/DE602004031239D1/de not_active Expired - Lifetime
- 2004-07-21 NZ NZ580855A patent/NZ580855A/en not_active IP Right Cessation
- 2004-07-21 DK DK04778714.8T patent/DK1660513T5/da active
- 2004-07-21 PL PL04778714T patent/PL1660513T3/pl unknown
-
2006
- 2006-01-05 IL IL172982A patent/IL172982A/en active IP Right Grant
- 2006-01-13 ZA ZA2006/00375A patent/ZA200600375B/en unknown
- 2006-01-19 EC EC2006006294A patent/ECSP066294A/es unknown
- 2006-01-20 MX MX2011000245A patent/MX336469B/es unknown
- 2006-01-20 CR CR8207A patent/CR8207A/es unknown
- 2006-02-20 NO NO20060812A patent/NO339324B1/no not_active IP Right Cessation
-
2010
- 2010-11-25 JP JP2010262151A patent/JP5643619B2/ja not_active Expired - Fee Related
-
2011
- 2011-04-21 CY CY20111100408T patent/CY1111938T1/el unknown
-
2014
- 2014-06-30 JP JP2014133794A patent/JP5997727B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-29 IL IL242336A patent/IL242336A/en active IP Right Grant
- 2015-12-04 JP JP2015237469A patent/JP6144749B2/ja not_active Expired - Fee Related
-
2017
- 2017-02-24 JP JP2017033672A patent/JP2017123857A/ja active Pending